Skip to main content
TipRanks
Go Ultimate75% OFF

Halozyme (0J2O) Share Price & Analysis

1 Followers

0J2O Stock Chart & Stats

$99.87-$1.68(-1.65%)
At close: 4:30 PM GMT
$100$110$120$130Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$99.42 - $102.67
52-Week Range
$59.85 - $133.94
Previous Close
$101.55
Volume
N/A
Average Volume (3M)
2,218
Market Cap
$11.43B
Enterprise Value
$15.71B
Total Cash (Recent Filing)
$1.07B
Total Debt (Recent Filing)
$3.25B
Price to Earnings (P/E)
23.9
Beta
0.74
Next Earnings
Feb 23, 2027 (Est.)
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Royalty Portfolio Growth

Broad-based royalty growth across multiple commercial products demonstrates that Halozyme is benefiting from expanding adoption of ENHANZE-enabled therapies. Diversification across partners and indications supports recurring revenue durability and reduces reliance on any single product over the next several quarters.

ENHANZE Pipeline Expansion

Expanded partner commitments and a growing clinical pipeline strengthen Halozyme’s platform economics by creating additional opportunities for milestones and future royalties. Multiple programs advancing toward commercialization can extend revenue growth and reinforce ENHANZE’s strategic value to drug developers.

Raised Growth And Margin Outlook

Management’s raised outlook combines rapid revenue and royalty growth with a very high projected adjusted EBITDA margin, indicating strong operating leverage in the licensing model. Sustained profitability and cash generation should support continued platform investment and capital allocation flexibility.

Bears Say

High Leverage And Negative Equity

Elevated debt alongside negative shareholder equity reduces financial flexibility and makes the capital structure more sensitive to any weakening in operating performance. Although cash generation is strong, substantial leverage can constrain investment choices and increase refinancing or repayment pressure.

U.S. Patent Litigation Risk

Adverse U.S. patent rulings create a lasting risk to the protection supporting Halozyme’s royalty economics, with the appeal process expected to continue likely until 2028. Unfavorable outcomes could weaken bargaining power, alter royalty durability, or increase litigation-related costs.

Potential Royalty Rate Pressure

Low starting royalty rates and possible patent-linked step-downs can reduce the economic contribution of newer partnerships compared with established agreements. As the portfolio expands, deal-level variability may make future royalty growth less profitable and less predictable than headline product adoption suggests.

Halozyme News

0J2O FAQ

What was Halozyme’s price range in the past 12 months?
Halozyme lowest share price was $59.85 and its highest was $133.94 in the past 12 months.
What is Halozyme’s market cap?
Halozyme’s market cap is $11.43B.
When is Halozyme’s upcoming earnings report date?
Halozyme’s next earnings report is estimated for Feb 23, 2027 (not yet confirmed), which is in 99 days.
How were Halozyme’s earnings last quarter?
Halozyme released its earnings results on Nov 05, 2026. The company reported $2.39 earnings per share for the quarter, beating the consensus estimate of $2.305 by $0.085.
Is Halozyme overvalued?
According to Wall Street analysts Halozyme’s price is currently Undervalued.
Does Halozyme pay dividends?
Halozyme pays a dividend of $0.285 which represents an annual dividend yield of ―. See more information on Halozyme dividends here
What is Halozyme’s EPS estimate?
Halozyme’s EPS estimate is 2.57.
How many shares outstanding does Halozyme have?
Halozyme has 114,010,000 shares outstanding.
What happened to Halozyme’s price movement after its last earnings report?
Halozyme reported an EPS of $2.39 in its last earnings report, beating expectations of $2.305. Following the earnings report the stock price went down -16.657%.
Which hedge fund is a major shareholder of Halozyme?
Hedge funds hold Halozyme shares: the largest hedge-fund position in Halozyme is 293,549,278 shares, and hedge funds increased their holdings by 28.4K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology